Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

<p>Baseline tumor H-score levels for AXL positivity by best confirmed overall response per investigator assessment in expansion cohorts. (A) Cohort 3 (Q3W): melanoma with BRAF V600 mutation; (B) cohort 4 (Q3W): melanoma with BRAF V600 wild-type; (C) cohort 5 (Q3W): sarcoma; (D) cohort 6 (3Q4W)...

Повний опис

Збережено в:

Бібліографічні деталі
Автор:	Kristoffer Staal Rohrberg (15009138) (author)
Інші автори:	Juanita S. Lopez (22687839) (author), Mohammed M. Milhem (15352499) (author), Christian U. Blank (14850778) (author), Irene Reijers (22687842) (author), Fiona Thistlethwaite (22687845) (author), Ruth Plummer (15028641) (author), Sarina A. Piha-Paul (15294428) (author), Pasi A. Jänne (14954872) (author), Elaine Shum (14955138) (author), Heather M. Shaw (22687848) (author), Philip R. Debruyne (20432881) (author), Cristopher Lao (22687851) (author), Jean-Francois Baurain (15031089) (author), Jennifer H. Choe (15052775) (author), Eelke Gort (17740951) (author), Yujie Zhao (22687854) (author), Guy Jerusalem (15017648) (author), Patrick Schöffski (15013461) (author), Andrew William Chen (22687857) (author), Eric A. Cohen (15017996) (author), Walter C. Mankowski (22687860) (author), Leonid Roshkovan (22687863) (author), Sharyn I. Katz (22687866) (author), Despina Kontos (15018005) (author), Lauren K. Brady (22687869) (author), Mohammed Qutaish (22687872) (author), Patricia Garrido Castro (22687875) (author), Nora Pencheva (22687878) (author), Gaurav Bajaj (22687881) (author), Yali Fu (22687884) (author), Kristian Windfeld (22687887) (author), Panagiota Reiter (22687890) (author), Maria Jure-Kunkel (15117740) (author), Brandon W. Higgs (15035279) (author), Katayoun I. Amiri (22687893) (author), Tahamtan Ahmadi (22687896) (author), Ulf Forssmann (22687899) (author), Suresh S. Ramalingam (14951413) (author), Ignace Vergote (15027870) (author)
Опубліковано:	2025
Предмети:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

_version_	1849927621939298304
author	Kristoffer Staal Rohrberg (15009138)
author2	Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870)
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author
author_facet	Kristoffer Staal Rohrberg (15009138) Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870)
author_role	author
dc.creator.none.fl_str_mv	Kristoffer Staal Rohrberg (15009138) Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870)
dc.date.none.fl_str_mv	2025-11-26T07:40:28Z
dc.identifier.none.fl_str_mv	10.1158/2767-9764.30719280
dc.relation.none.fl_str_mv	https://figshare.com/articles/figure/Figure_S2_from_Phase_I_II_Study_of_AXL-Specific_Antibody_Drug_Conjugate_Enapotamab_Vedotin_in_Patients_with_Advanced_Solid_Tumors/30719280
dc.rights.none.fl_str_mv	CC BY info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas
dc.title.none.fl_str_mv	Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
dc.type.none.fl_str_mv	Image Figure info:eu-repo/semantics/publishedVersion image
description	<p>Baseline tumor H-score levels for AXL positivity by best confirmed overall response per investigator assessment in expansion cohorts. (A) Cohort 3 (Q3W): melanoma with BRAF V600 mutation; (B) cohort 4 (Q3W): melanoma with BRAF V600 wild-type; (C) cohort 5 (Q3W): sarcoma; (D) cohort 6 (3Q4W): other metastatic solid tumors; and (E) cohort 7 (Q3W): platinum-resistant ovarian cancer . CR, complete response; PD, progressive disease; PR, partial response; Q3W, once every 3 weeks; 3Q4W, 3 weekly doses every 4 weeks; SD, stable disease</p>
eu_rights_str_mv	openAccess
id	Manara_dbe7dd8ba71f96979c7d77895b6e0b4e
identifier_str_mv	10.1158/2767-9764.30719280
network_acronym_str	Manara
network_name_str	ManaraRepo
oai_identifier_str	oai:figshare.com:article/30719280
publishDate	2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv	CC BY
spelling	Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid TumorsKristoffer Staal Rohrberg (15009138)Juanita S. Lopez (22687839)Mohammed M. Milhem (15352499)Christian U. Blank (14850778)Irene Reijers (22687842)Fiona Thistlethwaite (22687845)Ruth Plummer (15028641)Sarina A. Piha-Paul (15294428)Pasi A. Jänne (14954872)Elaine Shum (14955138)Heather M. Shaw (22687848)Philip R. Debruyne (20432881)Cristopher Lao (22687851)Jean-Francois Baurain (15031089)Jennifer H. Choe (15052775)Eelke Gort (17740951)Yujie Zhao (22687854)Guy Jerusalem (15017648)Patrick Schöffski (15013461)Andrew William Chen (22687857)Eric A. Cohen (15017996)Walter C. Mankowski (22687860)Leonid Roshkovan (22687863)Sharyn I. Katz (22687866)Despina Kontos (15018005)Lauren K. Brady (22687869)Mohammed Qutaish (22687872)Patricia Garrido Castro (22687875)Nora Pencheva (22687878)Gaurav Bajaj (22687881)Yali Fu (22687884)Kristian Windfeld (22687887)Panagiota Reiter (22687890)Maria Jure-Kunkel (15117740)Brandon W. Higgs (15035279)Katayoun I. Amiri (22687893)Tahamtan Ahmadi (22687896)Ulf Forssmann (22687899)Suresh S. Ramalingam (14951413)Ignace Vergote (15027870)CancerImmuno-oncologyClinical Research and TrialsClinical Trial ResultsImmunologyAntibodies/immunoconjugatesLung CancerMelanomaOvarian CancerSarcomas<p>Baseline tumor H-score levels for AXL positivity by best confirmed overall response per investigator assessment in expansion cohorts. (A) Cohort 3 (Q3W): melanoma with BRAF V600 mutation; (B) cohort 4 (Q3W): melanoma with BRAF V600 wild-type; (C) cohort 5 (Q3W): sarcoma; (D) cohort 6 (3Q4W): other metastatic solid tumors; and (E) cohort 7 (Q3W): platinum-resistant ovarian cancer . CR, complete response; PD, progressive disease; PR, partial response; Q3W, once every 3 weeks; 3Q4W, 3 weekly doses every 4 weeks; SD, stable disease</p>2025-11-26T07:40:28ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/2767-9764.30719280https://figshare.com/articles/figure/Figure_S2_from_Phase_I_II_Study_of_AXL-Specific_Antibody_Drug_Conjugate_Enapotamab_Vedotin_in_Patients_with_Advanced_Solid_Tumors/30719280CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307192802025-11-26T07:40:28Z
spellingShingle	Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Kristoffer Staal Rohrberg (15009138) Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas
status_str	publishedVersion
title	Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_full	Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_fullStr	Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_full_unstemmed	Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_short	Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_sort	Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
topic	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas

Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

Схожі ресурси